Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas P Miller

Showing results (41-50 of 62) with videos related to

Pageof 7
Sort By:
Leukemia & Lymphoma|January 14, 2016
A phase II study of belinostat (PXD101) in relapsed and refractory aggressive B-cell lymphomas: SWOG S0520Soham D Puvvada, Hongli Li, Lisa M Rimsza, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|August 19, 2007
Quantitative nuclease protection assay in paraffin-embedded tissue replicates prognostic microarray gene expression in diffuse large-B-cell lymphomaRobin A Roberts, Constantine M Sabalos, Michael L LeBlanc, et al.
Blood|March 18, 2006
Loss of major histocompatibility class II gene and protein expression in primary mediastinal large B-cell lymphoma is highly coordinated and related to poor patient survivalRobin A Roberts, George Wright, Andreas R Rosenwald, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 5, 2005
Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphomaMyron S Czuczman, Aron Thall, Thomas E Witzig, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 17, 2013
A comparative analysis of prognostic factor models for follicular lymphoma based on a phase III trial of CHOP-rituximab versus CHOP + 131iodine--tositumomabOliver W Press, Joseph M Unger, Lisa M Rimsza, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 13, 2012
Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016Oliver W Press, Joseph M Unger, Lisa M Rimsza, et al.
British Journal of Haematology|January 30, 2013
The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496Andrew M Evens, Fangxin Hong, Leo I Gordon, et al.
Blood|June 12, 2008
Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOPLisa M Rimsza, Michael L Leblanc, Joseph M Unger, et al.
American Journal of Hematology|March 18, 2014
Genetic polymorphisms in oxidative stress-related genes are associated with outcomes following treatment for aggressive B-cell non-Hodgkin lymphomaHeather L Gustafson, Song Yao, Bryan H Goldman, et al.
Blood|February 7, 2013
Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trialJennifer A Kanakry, Hailun Li, Lan L Gellert, et al.
Pageof 7

Showing results (41-50 of 62) with videos related to

Sort By:
Pageof 7
Leukemia & Lymphoma|January 14, 2016
A phase II study of belinostat (PXD101) in relapsed and refractory aggressive B-cell lymphomas: SWOG S0520Soham D Puvvada, Hongli Li, Lisa M Rimsza, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|August 19, 2007
Quantitative nuclease protection assay in paraffin-embedded tissue replicates prognostic microarray gene expression in diffuse large-B-cell lymphomaRobin A Roberts, Constantine M Sabalos, Michael L LeBlanc, et al.
Blood|March 18, 2006
Loss of major histocompatibility class II gene and protein expression in primary mediastinal large B-cell lymphoma is highly coordinated and related to poor patient survivalRobin A Roberts, George Wright, Andreas R Rosenwald, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 5, 2005
Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphomaMyron S Czuczman, Aron Thall, Thomas E Witzig, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 17, 2013
A comparative analysis of prognostic factor models for follicular lymphoma based on a phase III trial of CHOP-rituximab versus CHOP + 131iodine--tositumomabOliver W Press, Joseph M Unger, Lisa M Rimsza, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 13, 2012
Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016Oliver W Press, Joseph M Unger, Lisa M Rimsza, et al.
British Journal of Haematology|January 30, 2013
The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496Andrew M Evens, Fangxin Hong, Leo I Gordon, et al.
Blood|June 12, 2008
Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOPLisa M Rimsza, Michael L Leblanc, Joseph M Unger, et al.
American Journal of Hematology|March 18, 2014
Genetic polymorphisms in oxidative stress-related genes are associated with outcomes following treatment for aggressive B-cell non-Hodgkin lymphomaHeather L Gustafson, Song Yao, Bryan H Goldman, et al.
Blood|February 7, 2013
Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trialJennifer A Kanakry, Hailun Li, Lan L Gellert, et al.
Pageof 7